Delta what? Here's how to understand the difference between Delta 8, 9 and 10
These products, sold as smokables, edible desserts, candies and soft drinks, contain "Delta 8" or "Delta 10." These products can certainly result in a "high" that is like marijuana, but they aren't fully natural and don't include the compounds associated with medical and recreational marijuana.
In 2018, President Donald Trump signed the Agriculture Improvement Act, more commonly known as the Farm Bill, which removed hemp from the 1970 Controlled Substances Act. Previously, hemp was classified as a Schedule 1 drug alongside marijuana and other heavy drugs like heroin and methamphetamemes. Simply put, hemp production, manufacturing, sale and consumption is federally legal.
Delta 8 and Delta 10 both fall under this hemp category, as long as they contain 0.3% or less THC. This means products containing Delta 8 or Delta 10 can be sold in states where medical or recreational marijuana has yet to be legalized. Alternatively, Delta 9, the compound associated with medical and recreational marijuana, contains 0.3% or more THC and is not federally legal. It is regulated state by state.
So just what is the difference between all these "Deltas"? Here's what to know about the different cannabinoids on the market.
Delta 8, Delta 9 and Delta 10 are three of the more than 100 cannabinoids, or chemicals, that exist within the cannabis plant. Each is a form of THC (tetrahydrocannabinol), which is primarily responsible for marijuana's psychoactive effects.
Each of the cannabinoids can produce a "high" effect, but they all work a little differently.
Delta 8 is found in trace amounts of the cannabis plant, as it's produced when a cannabis plant ages, according to Leafwell, an online marijuana resource.
Because cannabis plants only produce a small amount of Delta 8, most Delta 8 products contain a synthesized form of the cannabinoid, which is made by rearranging the molecules of CBD (cannabidiol), according to Leafwell.
Delta 9 is the most abundant cannabinoid in marijuana. Discussions about medical and recreational marijuana, which are regulated at the state level, are about Delta 9.
Like Delta 8, Delta 10 is a trace cannabinoid in the cannabis plant. It is also often produced in a lab from CBD.
Though each of the cannabinoids may have different affects on the body, each interacts with the body's endocannabinoid system, which regulates bodily functions like mood, pain, sleep, appetite, memory, and reproduction and fertility, according to Healthline.
Delta 9 attaches to the body's endocannabinoid system more strongly than Delta 8 and Delta 10, meaning its effects are more potent, according to Leafwell. Users may feel a more intense high with Delta 9.
Delta 8 and Delta 10 are often available over the counter at convenience stores, smoke and vape shops and gas stations. Delta 9 is only available for purchase from licensed medical and adult-use marijuana dispensaries in states where marijuana is legal.
Age restrictions on purchasing THC products vary per state, but commonly consumers must be 18 or 21 to purchase products that contain Delta 8, 9 or 10.
Delta 8 and Delta 10 are both federally legal, as they are derived from hemp and contain low traces of THC. They are protected under the Farm Bill signed by Trump during his first term in 2018. However, some states have banned the sale and consumption of both Delta 8 and 10, citing health concerns.
Delta 9 is not federally legal but regulated on a state-by-state basis.
More: Where is marijuana legal in the US? Here's which states have legalized weed as 4/20 approaches
Yes, each of the cannabinoids can show up on a drug test. However, more commercial drug tests cannot differentiate between the cannabinoids, according to WedMD.
Historically, hemp, including Delta 8 and Delta 10, have not been as regulated or well researched as Delta 9. Though Delta 8 and Delta 10 are derived from the natural cannabis plant, the Food and Drug Administration advises consumers to be cautious of products that contain these compounds.
For example, some Delta 8 and Delta 10 products may be labeled simply as "hemp products," which may mislead consumers who associate "hemp" with "non-psychoactive." Additionally, because Delta 8 and Delta 10 are largely unregulated, some manufacturers may use unsafe chemicals to make the compounds, the FDA warns.
By and large, adults should always start by educating themselves before consuming any form of marijuana or hemp product and purchase products from licensed and/or regulated facilities.
Greta Cross is a national trending reporter at USA TODAY. Story idea? Email her at gcross@usatoday.com.
This article originally appeared on USA TODAY: Delta 8, 9 and 10: What makes the cannabis compounds different?
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
2 hours ago
- Newsweek
Californians Warned of 'Devastating' New Health Insurance Costs
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Health insurance costs are set to increase for Californians in 2026, and the state's health insurance marketplace has warned that the impacts could be a major burden on American families. This comes as health insurance premiums are expected to rise significantly across the country next year, when enhanced tax credits are set to expire, as President Donald Trump has not chosen to renew them. A spokesperson for Covered California told Newsweek: "The combined impact of the premium increases and the loss of enhanced premium tax credits would be devastating for Californians." "All Covered California enrollees would face higher costs, and the loss of enhanced tax credits alone could result in an average net premium increase of 66 percent for 1.7 million enrollees," they said. The spokesperson called it "a catastrophic financial burden for many, potentially pricing a significant number of individuals and families out of coverage." "Those with the lowest incomes would be hit hardest, as stagnant wages and rising inflation amplify their challenges." Why It Matters Aside from the expiration of enhanced tax credits, which will see 2026's rise in costs jump much higher than previous years, there are also a number of other factors pushing up premiums. These factors include increased health care costs, inflation, labor costs, and rising demand for medications such as GLP-1 drugs like Ozempic and Wegovy, which are driving up prescription drug spending. While premiums have been steadily increasing over the years, 2026 will see the largest hike in prices since 2018, according to KFF data. Agents help sign people up for insurance through the Covered California exchange at their storefront in Huntington Beach, California. Agents help sign people up for insurance through the Covered California exchange at their storefront in Huntington Beach, California. Nick Agro/The Orange County Register via AP What To Know Covered California recently announced that it would be increasing rates for health coverage in 2026 by an average of 10.3 percent across various health plans. Those on Affordable Care Act (ACA)-compliant plans will be affected, as the temporary subsidies for ACA marketplaces, introduced by former President Joe Biden to increase access to health coverage, will expire at the end of 2025. While there is still time for the Trump administration to opt to extend the subsidies, there has been no indication yet by the administration that they intend to, and the subsidies also come at a significant cost to the taxpayer. Covered California told Newsweek that its planned 10.3 percent increase is lower than the national average of 20 percent, with states like Florida having much higher proposed increases. The reason for the state marketplace's increase in premium costs is driven by several factors, the Covered California spokesperson told Newsweek, pointing to "rising health care and pharmacy costs, as well as broader industry challenges." They said that federal health care policies were also "contributing to these increases, particularly the expiration of federal enhanced premium tax credits at the end of 2025." "These credits have helped millions of Americans lower their premiums since 2021, and their expiration will have significant consequences for affordability nationwide," they said. The state marketplace previously said that Congress could reduce these price hikes for Americans by extending the enhanced tax credits, and that it hoped lawmakers on both sides of the aisle "recognize the need to extend this essential lifeline for working families." What People Are Saying A spokesperson for Covered California told Newsweek: "To mitigate these impacts, California is taking proactive steps to shield its lowest-income enrollees from steep increases. For 2026, the state has allocated $190 million from its cost-sharing reduction program to provide state subsidies for individuals earning up to 150 percent of the federal poverty level, helping keep premiums comparable to 2025 levels. "This assistance will benefit individuals with annual incomes of $23,475 or less and families of four earning up to $48,225. Additional support will also be available to those earning up to 165 percent of the federal poverty level." Jonathan Gruber, a professor of economics at Massachusetts Institute of Technology, told Newsweek: "Rates are certainly going to go up because of two changes: the [One Big Beautiful Bill] kicks some folks off exchanges and makes it harder for others to enroll and the additional subsidies that President Biden added to the exchanges are going to expire. When these changes happen it is the healthiest folks who will drop out of the exchanges, raising premiums for everyone else." He added, "This is disastrous for both economic security and health. Studies have shown that losing insurance is associated with enormous economic risk and worse health, including death." Ge Bai, a professor of health policy and management at Johns Hopkins Bloomberg School of Public Health, Maryland, told Newsweek: "ACA-compliant plans have always been expensive, but the federal government has made them appear affordable through taxpayer subsidies. The premiums we see now reflect their actual unaffordability, rather than the artificial affordability created by subsidies." She said: "While market characteristics may cause some state-to-state variations, the overall trend will be upward everywhere because the regulatory constraints driving up costs apply to ACA-compliant plans in all states." "ACA-compliant plans will become more expensive, especially for higher-income beneficiaries who lose subsidy eligibility. We urgently need to address the ACA's regulatory constraints that block affordable plans, rather than pouring taxpayer dollars into creating the illusion of affordability and worsening these plans' true unaffordability." What Happens Next The proposed increases are for the 2026 calendar year, and many are concerned about the impacts they will have on Americans.
Yahoo
4 hours ago
- Yahoo
Eli Lilly to hike U.K. Mounjaro Price 170% after Trump push
Eli Lilly is raising the price of the weight loss drug Mounjaro in the U.K., after President Donald Trump ramped up pressure on drugmakers to lower U.S. prices and raise them abroad. The price of the drug is expected to rise by up to 170% in September, increasing the cost of a monthly supply at the highest dose from £122 ($165) to £330 ($447). The company said it had agreed with the British government to raise prices while 'maintaining access' for patients covered by the U.K.'s National Health Service. Last month, Trump wrote to 17 of the world's biggest drugmakers , including Eli Lilly, Novo Nordisk, and Pfizer, demanding they slash prices for U.S. consumers as part of his 'most favored nation' policy. The scheme aims to bring down drug prices by tying charges in the U.S. to lower ones abroad. Eli Lilly said Thursday that it has 'intensified efforts to align prices across developed countries, especially in Europe'. 'We are continuing to work with certain governments and expect to make any necessary pricing adjustments by September 1, while providing continued access for patients,' it said. Prescription drug prices in the U.S. are often two to three times higher on average than those in other developed nations, according to the nonprofit Commonwealth Fund. The list price for a month's supply of Mounjaro in the U.S. is $1,079.77 before insurance. Eli Lilly added that it supports Trump's goal of keeping the U.S. the 'world's leading destination for biopharmaceutical research and manufacturing, and the objective of more fairly sharing the costs of breakthrough medical research across developed countries.' 'This rebalancing may be difficult, but it means the prices for medicines paid by governments and health systems need to increase in other developed markets like Europe in order to make them lower in the US,' it said. Trump wrote in July that he would 'deploy every tool in our arsenal to protect American families from continued abusive drug pricing practices' if companies did not comply with his demands, saying other countries had been 'freeloading on U.S. innovation'. Meanwhile, the pharmaceutical industry is bracing for planned U.S. tariffs of medicines imported into the country. Eli Lilly said Thursday that it opposes the tariffs, saying they will raise costs and limit access to drugs. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16 hours ago
- Yahoo
Trade-offs abound as big pharma makes direct-to-consumer transition
Novo Nordisk is the latest drugmaker to slash the price of a blockbuster medicine via its online platform amid drug pricing reforms in the US, but analysis shows a smooth transition to direct-to-consumer (DTC) channels will be tricky. US President Donald Trump has made reducing drug prices in the country one of his administration's key targets. He has spearheaded this goal with the Most Favoured Nation (MFN) policy, a legislative framework that would tie US drug prices to the lowest prices in other developed countries. As part of this push, Trump has urged pharmaceutical companies to embrace DTC business models. This includes companies establishing their own platforms or opting in to those from third parties that cut out middlemen, meaning final drug prices are lower. GlobalData's senior pharma strategic intelligence analyst Wafaa Hassan comments: 'The [DTC] development, closely tied to the administration's 'America First' healthcare agenda and its revived MFN pricing framework, marks a renewed phase of pressure on drugmakers to lower domestic prices while signalling alignment between the White House and the pharmaceutical industry.' Earlier this year, Novo Nordisk unveiled its DTC platform NovoCare Pharmacy with a heavily discounted price for weight loss drug Wegovy (semaglutide). Just this week, the drugmaker added type 2 diabetes treatment Ozempic (semaglutide) to the platform. Both drugs are available to cash-paying patients for $499 each for a monthly supply. The list price of both drugs in the US sits at around $1,300 per month. While the move to discount the two drugs is more likely a response to the popularity of cheaper compounded alternatives, Trump will nevertheless be pleased with Novo's decision. Ozempic – a drug that generated global sales of $10bn in Q2 this year alone – being available for cheaper on a DTC platform is a coup Trump will likely point to in the face of criticism for his pricing reforms. However, challenges such as a limited patient awareness and disruption to traditional distribution channels could hinder the adoption of the DTC models by pharma companies, according to analysis by GlobalData. Hassan adds: 'From a drugmaker perspective, more challenges will occur following the initiatives, such as new operational demands, margin pressure and potential friction with insurers. The likelihood of success will only depend on how well the pharma industry navigates these trade-offs in the upcoming months.' Novo is far from the only big pharma company bolstering DTC medicine offerings. Novo's main rival in the GLP-1RA arena, Eli Lilly, has also conducted similar moves. The company began offering its weight loss medication Zepbound (tirzepatide) to self-paying patients at a steep discount on its own DTC platform LillyDirect in 2024. Taking a page from the two GLP-1RA developers, Bristol Myers Squibb (BMS) and Pfizer also established a DTC online programme for their blockbuster blood thinner Eliquis (apixaban) in July. BMS, Pfizer, Eli Lilly, and Novo Nordisk were among 17 pharma companies to receive a letter from Trump requesting more steps be taken by them to cut drug prices. "Trade-offs abound as big pharma makes direct-to-consumer transition" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
